What If MI Patients Got Their Follow-Up Meds for Free?

In a cluster-randomized study, improvement in adherence — and in some outcomes — was significant but small.

Prescription of evidence-based medications after acute myocardial infarction (AMI) has increased substantially over the past decade. However, prescription does not ensure benefit; patients must obtain and take the drugs. In this study, sponsored by a large U.S. commercial insurer, investigators assessed full prescription coverage for evidence-based drug therapy following AMI in 5855 patients (mean age, 54; 75% men). Participants were randomized at the level of the health-plan sponsor to either full or usual coverage for angiotensin-converting–enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta-blockers, and statins.

Average monthly co-payments in the usual-coverage group were $13.35 for ACE inhibitors or ARBs, $12.83 for beta…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)